Michael Zinda, EVP, Chief Science Officer at Repare Therapeutics Inc. (RPTX), sold 74,214 shares at $33.36 ($2.5M) on 2020-12-22, disclosed to the SEC on 2020-12-28.
Open-market sale of $2.5M RPTX by EVP, Chief Science Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $33.36 | 39,700 | $1.3M | 53.3% |
| 2 | $34.00 | 1,612 | $55K | 2.2% |
| 3 | $33.48 | 12,556 | $420K | 16.9% |
| 4 | $33.48 | 12,556 | $420K | 16.9% |
| 5 | $34.26 | 3,679 | $126K | 5.1% |
| 6 | $34.26 | 3,679 |
| $126K |
| 5.1% |
| 7 | $33.14 | 432 | $14K | 0.6% |
| Total | $33.50 avg | 74,214 | $2.5M | 100% |
| Filing → |
| RPTX | SELL | 2024-03-27 | $6K | — | Filing → |
| RPTX | SELL | 2023-06-09 | $189K | — | Filing → |
| RPTX | SELL | 2023-06-07 | $14K | — | Filing → |